Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Nicox logo — Maintain vision and improve ocular health

Nicox

Maintain vision and improve ocular health

Founded 1996 France France 46 employees Post-IPO Equity Total: $197.30M Biotechnology, Health Care +1

General Information

Company Name Nicox
Founded Year 1996
Location France France
Employees 46
Industries Biotechnology, Health Care, Medical Devices
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Nicox. To contact Nicox, visit nicox.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Nicox compare?

A PDF of Nicox and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Nicox soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Nicox

Nicox, an international ophthalmic R&D company, has been dedicated to maintaining vision and improving ocular health since its establishment in 1996. With a focus on biotechnology, healthcare, and medical devices, the company is committed to building a diversified portfolio of therapeutic products to meet the needs of eyecare practitioners and patients globally. Nicox's global growth strategy revolves around outstanding international collaborations and its proprietary programs, including those from its nitric oxide-donating research platform. The most recent development for Nicox took place on July 18, 2024, with a €3.30M Post-IPO Equity investment. This investment, although not disclosed with specific investors, signifies a potential milestone for the company. The headquarter of Nicox is located in France. For further information, individuals can visit their website at www.nicox.com.

Business keywords: biopharmaceuticals, ophthalmology, nitric oxide-donating drugs, inflammation, cardiovascular diseases, osteoarthritis, glaucoma treatment, respiratory disorders, allergic rhinitis, hypertension treatment, skin disorders, diabetic retinopathy, collaborations, drug development

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity €3.30M -
18 Jul 2024
Post IPO Equity €10.00M -
22 Nov 2022
Post IPO Equity €15.00M -
09 Dec 2021
Post IPO Debt €20.00M 1
Kreos Capital
Kreos Capital
25 Jan 2019
Post IPO Equity $149.00M -
18 Nov 2009

Nicox Alternatives & Competitors

View All Alternatives
Nicox vs
BioLum Sciences
BioLum Sciences United States

Transforming Precision Drug Discovery and Early Detection of Disease

Grant
5 employees
Biotechnology, Digital Health
Nicox vs
Inflammx Therapeutics, Inc.
Inflammx Therapeutics, Inc. United States

Modulation of Inflammasome mediated Autoinflammation - in Ophthalmology, Nephropathy and Neurodegen...

Venture round
3 employees
Biotechnology, Health Care
Nicox vs
Othera Pharmaceuticals
Othera Pharmaceuticals United States

Othera is a pharmaceutical company developing novel therapeutics for age-related diseases of the eye...

Debt Financing
27 employees
Biotechnology, Health Care
View all alternatives

FAQ About Nicox

Maintain vision and improve ocular health
Nicox was founded in 1996.
Nicox is headquartered in France.
Nicox operates in Biotechnology, Health Care and Medical Devices. Its work centres on biopharmaceuticals, ophthalmology, nitric oxide-donating drugs and inflammation.
Nicox has approximately 46 employees.
Nicox has completed 5 funding rounds, raising a total of $197.30M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Nicox include BioLum Sciences, Inflammx Therapeutics, Inc., Othera Pharmaceuticals, Inotek Pharmaceuticals, Myrobalan Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Nicox and BioLum Sciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Nicox, https://bouncewatch.com/company/nicox, updated 20 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes